NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIDCR E-152-2017-0-DE-06 FORMATION OF STABLE CARTILAGE DE EP 18737743.7 Issued
NIDCR E-152-2017-0-FR-07 FORMATION OF STABLE CARTILAGE FR EP 18737743.7 Issued
NIDCR E-152-2017-0-IL-04 FORMATION OF STABLE CARTILAGE IL National Stage 1991-08-27 Issued
NIDCR E-152-2017-0-PCT-02 FORMATION OF STABLE CARTILAGE PCT PCT PCT/US2018/035448 Expired
NIBIB E-062-2017-0-PCT-02 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging PCT PCT PCT/US2018/035303 Expired
NHLBI E-217-2015-0-US-06 Fluorescent Nanodiamonds As Fiducial Markers For Microscopy And Fluorescence Imaging US National Stage 15/780,388 Abandoned
NIBIB E-062-2017-0-EP-04 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging EP National Stage 18810466.5 Pending
NIBIB E-062-2017-0-IL-05 Systems and Methods for Three-Dimensional Fluorescence Polarization Via Multiview Imaging IL National Stage 2042-10-27 Pending
NHGRI E-110-2017-0-PCT-02 Methods of Detecting and Treating GATM-Related Renal Disorders PCT PCT PCT/US2018/035423 Expired
NCATS E-299-2012-0-US-07 BMP Inhibitors and Methods of Use Thereof US CON 15/994,604 Abandoned
NCI E-015-2018-0-US-01 METHOD FOR TREATING OR PREVENTING PERIODONTITIS WITH GEOPROPOLIS EXTRACT US 62/678,774 Abandoned
NIAID E-103-2014-3-AU-09 Antibody Evolution Immunogens AU DIV 2018203805 Abandoned
NIAID E-042-2018-0-JP-06 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE JP National Stage 2019-565890 Issued
NIAID E-042-2018-0-CN-04 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE CN National Stage 201880048358.8 Pending
NIAID E-042-2018-0-EP-05 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE EP National Stage 18733056.8 Pending
NIAID E-067-2016-3-EP-02 A Novel Method Of Vaccination With An Attenuated RSV Vaccine Formulation EP National Stage 16794904.9 Pending
NIAID E-042-2018-0-JP-01 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE JP DIV 2023-063846 Pending
NIAID E-042-2018-0-CA-03 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE CA National Stage 3064267 Pending
NIAID E-042-2018-0-PCT-02 RECOMBINANT CHIMERIC BOVINE/HUMAN PARAINFLUENZA VIRUS 3 EXPRESSING RSV G AND ITS USE PCT PCT PCT/US2018/034848 Expired
NCATS E-004-2016-0-US-08 BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF US National Stage 15/779,353 10508106 Issued PDF
NIAID E-052-2017-4-NZ-39 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection NZ National Stage 742825 Issued
NIAID E-191-2018-0-US-01 Improved Methods Of Manufacturing Peptide-Based Vaccines US 62/674,752 Abandoned
NIAID E-202-2008-0-US-18 INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS US DIV 15/984,956 10881669 Issued PDF
NCI E-213-2014-0-US-06 Methodology For Astatination And Radioiodination Based On Iodonium Salt Precursors US National Stage 15/777,828 10703708 Issued PDF
NCI E-285-2016-2-SI-01 Glypican 2 As A Cancer Marker And Therapeutic Target SI EP 16864859.0 Issued
NCI E-285-2016-2-RS-01 Glypican 2 As A Cancer Marker And Therapeutic Target RS EP 16864859.0 Issued
NCI E-285-2016-2-MK-01 Glypican 2 As A Cancer Marker And Therapeutic Target MK EP 16864859.0 Issued
NCI E-285-2016-2-SE-01 Glypican 2 As A Cancer Marker And Therapeutic Target SE EP 16864859.0 Issued
NCI E-285-2016-2-SK-01 Glypican 2 As A Cancer Marker And Therapeutic Target SK EP 16864859.0 Issued
NCI E-285-2016-2-RO-01 Glypican 2 As A Cancer Marker And Therapeutic Target RO EP 16864859.0 Issued
NCI E-285-2016-2-PL-01 Glypican 2 As A Cancer Marker And Therapeutic Target PL EP 16864859.0 Issued
NCI E-285-2016-2-BG-01 Glypican 2 As A Cancer Marker And Therapeutic Target BG EP 16864859.0 Issued
NCI E-285-2016-2-AL-01 Glypican 2 As A Cancer Marker And Therapeutic Target AL EP 16864859.0 Issued
NCI E-285-2016-2-BE-01 Glypican 2 As A Cancer Marker And Therapeutic Target BE EP 16864859.0 Issued
NCI E-285-2016-2-LU-01 Glypican 2 As A Cancer Marker And Therapeutic Target LU EP 16864859.0 Issued
NCI E-285-2016-2-MT-01 Glypican 2 As A Cancer Marker And Therapeutic Target MT EP 16864859.0 Issued
NCI E-285-2016-2-LV-01 Glypican 2 As A Cancer Marker And Therapeutic Target LV EP 16864859.0 Issued
NCI E-285-2016-2-MC-01 Glypican 2 As A Cancer Marker And Therapeutic Target MC EP 16864859.0 Issued
NCI E-285-2016-2-NL-01 Glypican 2 As A Cancer Marker And Therapeutic Target NL EP 16864859.0 Issued
NCI E-285-2016-2-LT-01 Glypican 2 As A Cancer Marker And Therapeutic Target LT EP 16864859.0 Issued
NCI E-285-2016-2-EP-04 Glypican 2 As A Cancer Marker And Therapeutic Target EP National Stage 16864859.0 Issued
NCI E-285-2016-2-CZ-01 Glypican 2 As A Cancer Marker And Therapeutic Target CZ EP 16864859.0 Issued
NCI E-285-2016-2-HR-01 Glypican 2 As A Cancer Marker And Therapeutic Target HR EP 16864859.0 Issued
NCI E-285-2016-2-EE-01 Glypican 2 As A Cancer Marker And Therapeutic Target EE EP 16864859.0 Issued
NCI E-285-2016-2-DK-01 Glypican 2 As A Cancer Marker And Therapeutic Target DK EP 16864859.0 Issued
NCI E-285-2016-2-DE-01 Glypican 2 As A Cancer Marker And Therapeutic Target DE EP 16864859.0 Issued
NCI E-285-2016-2-GB-01 Glypican 2 As A Cancer Marker And Therapeutic Target GB EP 16864859.0 Issued
NCATS E-257-2010-0-US-19 SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS US DIV 15/983,844 10925874 Issued PDF
NCI E-150-2018-0-US-01 CATALYTICALLY HYPERACTIVE VARIANT OF HUMAN APOBEC3G PROTEIN US 62/673,591 Abandoned
NIAID E-136-2013-0-US-06 Single-Domain VHH Antibodies Directed to Norovirus GI.1 And GII.4 And Their Use US DIV 15/982,998 10662238 Issued PDF